Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by jimmyhorizonon Feb 10, 2022 2:58am
154 Views
Post# 34415378

RE:RE:RE:RE:RE:0.27

RE:RE:RE:RE:RE:0.27has the company ever communicated a negative development in a timely manner?

sirona communication goes like this:

the big breakthrough with the world's big players in giant markets is imminent.

then time passes without results.

many excuses are found: slow lawyers, big sluggish companies, restructuring processes at the partners, crazy long timelines (what otherwise takes 3-6 weeks, takes at minimum 2 years at sirona), covid, discussions with new partners and so on

Then wexi is slowly shifting his time horizons on the board. the wording in the investor presentations is being adjusted. only grammar of course.

and then a few years later, in a two-line statement, it is admitted that the project has failed or timelines that have not been met are simply no longer discussed.

the only thing that can be accepted as a statement of fact at sirona is the non-announcement of a deal.

when new partners are mentioned in the investor presentation and wexi shifts the time horizon backwards, this means only one thing: TOP 10 Pharma walked away.

This is how it has been in the past, and the likelihood that it will be again increases with each passing day.

the facts are: the clinical trial was completed on March 31, 2021. due diligence was completed in september 2021. that´s five months ago. far too long for finalizing the paperwork.

look at this piece of art:

https://www.youtube.com/watch?v=FgpWDYBZyqs

what in there is true except some company names? do you come up with prc-partners because of some expiring warrants?

the only business model i can see is leading the public around by the nose.

what if the public doesn't put up with it? ever thought about that?








<< Previous
Bullboard Posts
Next >>